secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-08-17T12:30:07+00:00
Accession:  0001193125-26-353278
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum to merge with Slate Medicines; Slate holders to own ~95% of combined company
--------------------------------------------------------------------------------

- Merger values Slate at $350M, Fulcrum at $31.3M; post-close ownership: Slate holders ~55.9%, investors ~39.1%, Fulcrum ~5.0%.
- $245M concurrent investment from existing Slate stockholders and new investors; combined cash runway into 2029.
- Fulcrum to pay $270M cash dividend to pre-merger Fulcrum stockholders; company renamed Slate Medicines, Inc.
- Fulcrum board set at 5 members, all designated by Slate; Fulcrum options with exercise price >$7.00 cancelled at close.
- Termination fees: Fulcrum pays $10M, Slate pays $15M; Slate stockholders holding 78.65% support deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/0001193125-26-353278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526353278/d136791d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-353278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer